
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Ernexa Therapeutics (NASDAQ: ERNA) is developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease. Ernexa's core technology focuses on engineering induced pluripotent stem cells (iPSCs) and transforming them into induced mesenchymal stem cells (iMSCs). Ernexa's a... Ernexa Therapeutics (NASDAQ: ERNA) is developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease. Ernexa's core technology focuses on engineering induced pluripotent stem cells (iPSCs) and transforming them into induced mesenchymal stem cells (iMSCs). Ernexa's allogeneic synthetic iMSCs provide a scalable, off-the-shelf treatment solution, without needing patient-specific cell harvesting. Show more
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.2835 | -10.3335155823 | 2.7435 | 2.7493 | 2.08 | 927351 | 2.34961695 | CS |
4 | -0.993 | -28.7576020851 | 3.453 | 3.749985 | 2.08 | 729763 | 2.80940088 | CS |
12 | -1.515 | -38.1132075472 | 3.975 | 4.0185 | 2.08 | 378921 | 2.90592534 | CS |
26 | -1.6245 | -39.7723099523 | 4.0845 | 14.4 | 2.08 | 5445710 | 6.69503878 | CS |
52 | -26.94 | -91.6326530612 | 29.4 | 39.375 | 2.08 | 2839905 | 6.65001775 | CS |
156 | -60.54 | -96.0952380952 | 63 | 107.25 | 2.08 | 1082754 | 7.68188139 | CS |
260 | -60.54 | -96.0952380952 | 63 | 107.25 | 2.08 | 1082754 | 7.68188139 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions